Evidence map›Paper›PMID 41869663›Full record

ArticleFrontiers in oncology2026

Rare renal tumor: a case report of collecting duct carcinoma and literature review.

Cheng Zhu, Yingfang Zhang, Zhong Tian, Tingting Yang, Guang Han, Huangyu Luo, Bo Yu, Neng Zhang, Ni Fu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cheng Zhu *Department of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Yingfang Zhang *Department of Nursing, The Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhong TianDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Tingting YangDepartment of Pathology, The Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Guang HanDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Huangyu LuoDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Bo YuDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Neng ZhangDepartment of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Ni FuDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Collecting duct carcinoma (CDC), also known as Bellini duct carcinoma, is an extremely rare and highly aggressive subtype of renal cell carcinoma. Most patients present with metastasis at the time of diagnosis, and the prognosis for CDC patients is generally poor. Surgery is the primary treatment approach. In this article, we report a case of CDC presenting primarily with hematuria and provide a comprehensive review of the published literature concerning its diagnosis, treatment, and prognosis. The aim is to enhance understanding of this rare renal malignancy by elucidating its clinical and pathological characteristics and supplementing relevant treatment experiences.

Indexed as

aggressive renal cell carcinomacase reportcollecting duct carcinomadifferential diagnosismetastasisrare disease

Identifiers

PMID41869663
PMCPMC12999396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.